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Background: The NAPOLI-1 trial demonstrated that liposomal irinotecan in combination
with ﬂuorouracil (5-FU) and leucovorin (LV) prolonged survival with a manageable
safety proﬁle in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
previously treated with gemcitabine-based therapy. Real-world data on clinical outcomes
associated with liposomal irinotecan in NAPOLI-1-based regimens is needed to further
substantiate this.
Methods: This real-world, retrospective chart review study included patients with
mPDAC who received NAPOLI-1-based regimens from six academic centers in the
United States. Liposomal irinotecan initiation deﬁned the index date. Overall survival (OS)
and progression-free survival (PFS) were assessed with Kaplan-Meier methodology.
Results: There were 374 patients evaluated; median age was 68 years, and 51% were
female. Among 326 patients with baseline ECOG information, approximately 74% had
ECOG score <2. Liposomal irinotecan was administered as a doublet with 5-FU in a
NAPOLI-1-based regimen in the ﬁrst line (1L; 16%), 2L (42%), and 3L+ (42%) of the
metastatic setting. For patients treated in 1L, 2L, and 3L+, median [95% conﬁdence
interval (CI)] OS was 8.0 [5.1, 11.2], 7.3 [5.3, 8.8], and 4.6 [4.0, 5.7] months, and median
[95% CI] PFS was 4.2 [2.2, 6.6], 3.0 [2.6, 3.7], and 2.0 [1.7, 2.2] months, respectively.
Conclusions: Patients in a real-world setting treated with NAPOLI-1-based liposomal
irinotecan doublet regimens at academic centers were older with poorer performance
status compared to trial patients yet had similar outcomes and efﬁcacy. Furthermore,
liposomal irinotecan was frequently used in the 3L+ setting where no treatment has been
approved and provided clinical beneﬁt.
Keywords: metastasis, pancreatic ductal adenocarcinoma, cancer management, pancreatic cancer,
liposomal irinotecan
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similar results (median OS 5.3 months and median PFS 2.9
months) to NAPOLI-1 (7). To expand on the aforementioned
study’s ﬁndings, this real-world study incorporated patients from
ﬁve additional cancer centers across the United States (US) in
order to assess real-world outcomes, treatment patterns, and
adverse events (AE) in patients with mPDAC treated with
liposomal irinotecan in a NAPOLI-1-based doublet regimen.

INTRODUCTION
Despite recent diagnostic and therapeutic advances, pancreatic
cancer remains an aggressive and difﬁcult to treat malignancy.
Although it only comprises 3% of new cancer diagnoses, it is
projected to be the second leading cause of cancer-related
mortality by 2030 (1). Due to an absence of effective screening
tools, pancreatic cancer is frequently diagnosed when locally
advanced or widely metastatic. Delayed diagnosis contributes to
treatment challenges as surgical resection is the only means to
curative treatment and is a factor in the poor 5-year survival rate
ranging from 3-8% (2).
In October 2015, the Food and Drug Administration (FDA)
approved liposomal irinotecan in combination with 5ﬂuorouracil (5-FU) and leucovorin (LV) for the treatment of
metastatic pancreatic ductal adenocarcinoma (mPDAC) in
patients that had previously progressed on gemcitabine-based
chemotherapy following the results of the pivotal NAPOLI-1
trial. The NAPOLI-1 trial evaluated liposomal irinotecan in
combination with 5-FU/LV compared to treatment with 5-FU/
LV alone in patients with mPDAC previously treated with
gemcitabine-based therapy (3). The results indicated that
treatment with liposomal irinotecan in combination with 5FU/LV compared to 5-FU/LV alone signiﬁcantly prolonged the
median overall survival (OS) (6.1 months vs. 4.2 months; hazard
ratio [HR]: 0.67; p: 0.012) and median progression-free survival
(PFS) (3.1 months vs. 1.5 months; HR: 0.56; p: 0.0001) in patients
with mPDAC. Liposomal encapsulation prolongs the duration of
circulating irinotecan prior to conversion to its active metabolite
SN-38, thereby protecting irinotecan from hydrolysis and rapid
metabolic conversion (4, 5). Liposomal irinotecan in
combination with 5-FU/LV is the only category 1 treatment
recommended by the National Comprehensive Cancer Network
(NCCN) for patients with mPDAC after disease progression
following gemcitabine-based therapy (6).
While the NAPOLI-1 trial results have expanded the
treatment options for mPDAC, there are limited real-world
data evaluating the use and outcomes of treatment with
liposomal irinotecan. A single institution study conducted at
Memorial Sloan Kettering Cancer Center (MSKCC) in 2017
assessed similar treatment outcomes among patients with
mPDAC treated with liposomal irinotecan and reported

METHODS
Study Design and Study Population
This was a non-interventional, retrospective, multi-center chart
review study that was conducted using data from six academic
cancer centers across the US. Participating centers included
MSKCC, Cedars-Sinai Medical Center, Emory Winship Cancer
Institute, Houston Methodist Cancer Center, Henry Ford Cancer
Institute, and University of Pittsburgh Medical Center. Eligible
patients were treated with liposomal irinotecan in a doublet with
5-FU between 2015 and 2020 and were diagnosed with mPDAC
at any time before liposomal irinotecan initiation. Following IRB
approval at each participating center, designated abstractors
collected patient demographics, clinical characteristics and
outcomes, and treatments from patient medical charts and
electronic medical records using a standardized electronic case
report form (eCRF). This study was conducted in two phases: a
pilot phase and a full-launch phase. During the pilot phase, the
eCRF was prepared and tested at one center using data from ten
patient charts. Reviewers ensured that the eCRF accurately
captured all relevant information and that data was collected
as efﬁciently as possible. Based on feedback from the pilot phase,
the eCRF was then updated and ﬁnalized for the full launch
phase where data collection began at all centers.
Patient data were collected during the baseline and
observation periods before and after the initiation of liposomal
irinotecan, the index date. The baseline period captured data
available prior to the index date (until the date of initial
pancreatic cancer diagnosis if available). Study outcomes were
assessed during the observation period, deﬁned as the period
from the index date to the end of data availability or
death (Figure 1).

FIGURE 1 | Study Design.
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TABLE 1 | Baseline demographic and clinical characteristics.

Study Variables and Outcomes
Patient demographics (e.g., age, region) and clinical
characteristics (e.g., Eastern Cooperative Oncology Group
[ECOG] performance status) were assessed during the baseline
period or at index date. For patients with missing baseline ECOG
performance status, their Karnofsky Performance Status (KPS)
scores were converted to ECOG status.
Study outcomes included treatment patterns, real-world
effectiveness (i.e., OS and PFS), and grade 3 or 4 AEs.
Duration of liposomal irinotecan treatment was deﬁned as the
time from index date to discontinuation. Treatment patterns of
therapies received in the metastatic setting prior to liposomal
irinotecan were examined. Two deﬁnitions of OS were used: (1)
OS from mPDAC diagnosis to death, and (2) OS from index date
to death. PFS was calculated from index date to the earliest of
disease progression or death. Clinically meaningful symptomrelated grade 3 or 4 AEs were reported, based on the Common
Terminology Criteria for Adverse Events (8).

N = 374
Demographic Characteristics
Age (years) at index, mean ± SD [median]
Female, n (%)
Race/Ethnicity, n (%)
White
Black/African-American
Asian/Paciﬁc Islander
Hispanic/Latino
Native American/American Indian
Unknown
Geographic location, n (%)
Northeast
South
West
Midwest
Year of index, n (%)
2015
2016
2017
2018
2019
2020
Clinical Characteristics
Time from mPDAC diagnosis to index (months),
mean ± SD [median]
Cancer stage at ﬁrst diagnosis of PDAC, n (%)
IA
IB
II A
II B
III
IV
Unknown
Liposomal irinotecan line of therapy, n (%)
1L
2L
3L+
Primary tumor location in pancreas, n (%)
Head
Body
Tail
Body and tail
Neck
Neck and body
Unknown
Metastatic sites, n (%)a
Liver
Lung
Peritoneum
Distant lymph nodes
Bone
Brain
Otherb
Number of metastatic sites, n (%)
1
2
3 or more
ECOG performance score, n (%)
0
1
2
3

Statistical Analyses
Summary statistics were presented as means, standard deviations
(SDs), and medians for continuous variables or frequencies and
proportions for categorical variables. Time to event analyses were
conducted using Kaplan-Meier methodology. For OS, patients
were censored at the end of data availability, and for PFS,
patients were censored at liposomal irinotecan discontinuation
or end of data availability. Time to event analyses were stratiﬁed
by the line of therapy in the metastatic setting that patients
received liposomal irinotecan [i.e., ﬁrst-line (1L), second-line
(2L), or third-line or later (3L+)].
The association between baseline characteristics and effectiveness
outcomes [i.e., OS (from index), PFS] was analyzed using a Cox
proportional hazards model. HRs, 95% conﬁdence intervals (CIs),
and p-values were reported. P-values from all statistical tests were
reported based on an alpha level of 0.05. All analyses were performed
using SAS version 9.4 (SAS Institute, Inc., Cary, NC).

RESULTS
Baseline Characteristics
374 patients met the study eligibility criteria and were included in
this study (Table 1). The mean ± SD [median] age at index date
was 67.8 ± 9.4 [68.6] years, and 51.3% of patients were female.
Most patients were white (71.7%), from the Northeast (57.0%),
and initiated liposomal irinotecan treatment in 2018 (32.6%) or
2019 (24.9%). The majority of patients (50.8%) had stage IV
pancreatic cancer at initial diagnosis. Patients were treated with
liposomal irinotecan in the 1L (17%), 2L (42%), or 3L+ (42%) of
the metastatic setting. Among patients treated with liposomal
irinotecan in 3L+, 57.0% were treated with a 5-FU-based regimen
and 41.7% were treated with a gemcitabine-based regimen in 1L
setting; 53.2% were treated with a gemcitabine-based regimen
and 34.6% were treated with a 5-FU-based regimen in 2L setting.
Among 326 patients with available performance status

Frontiers in Oncology | www.frontiersin.org

67.8 ± 9.4 [68.6]
192 (51.3)
268 (71.7)
48 (12.8)
26 (7.0)
13 (3.5)
1 (0.3)
18 (4.8)
213 (57.0)
78 (20.9)
57 (15.2)
26 (7.0)
1 (0.3)
63 (16.8)
82 (21.9)
122 (32.6)
93 (24.9)
13 (3.5)
10.9 ± 9.9 [8.4]

4 (1.1)
6 (1.6)
22 (5.9)
52 (13.9)
72 (19.3)
190 (50.8)
28 (7.5)
62 (16.6)
156 (41.7)
156 (41.7)
207 (55.3)
65 (17.4)
62 (16.6)
32 (8.6)
2 (0.5)
1 (0.3)
5 (1.3)
258 (69.0)
87 (23.3)
79 (21.1)
51 (13.6)
16 (4.3)
3 (0.8)
25 (6.7)
280 (74.9)
57 (15.2)
37 (9.9)
32 (8.6)
211 (56.4)
73 (19.5)
8 (2.1)
(Continued)
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TABLE 1 | Continued

characteristics. The overall median [95% CI] treatment
duration of liposomal irinotecan was 1.6 [1.4, 1.9] months and
was 2.8 [1.4, 5.6], 2.1 [1.6, 2.8], and 1.4 [1.3, 1.6] months for
patients treated with liposomal irinotecan in 1L, 2L, and 3L+,
respectively. Twenty three patients had treatment duration of
liposomal irinotecan longer than 12 months, 82.6% of whom
were treated with liposomal irinotecan in 1L or 2L. In addition, 9
patients had treatment duration of liposomal irinotecan longer
than 18 months, and 5 patients had treatment duration of
liposomal irinotecan longer than 24 months. Among 2L
patients (n=156), 1.3% had prior irinotecan, and among 3L
patients (n=156), 57.7% had prior irinotecan in the metastatic
setting. Among 367 patients with dosing information, 29.4%
patients had dose reduction at any time during liposomal
irinotecan treatment. 7.0% of patients received granulocyte
colony stimulating factor (GCSF) with their ﬁrst
administration of liposomal irinotecan.

N = 374
4
Unknown
Selected comorbidities, n (%)a,c
Diabetes without end-organ damage
Peripheral vascular disease
Diabetes with end-organ damage
Chronic obstructive pulmonary disease
Moderate or severe renal disease
Congestive heart failure
Cerebrovascular disease

2 (0.5)
48 (12.8)
95 (25.4)
16 (4.3)
16 (4.3)
12 (3.2)
12 (3.2)
10 (2.7)
9 (2.4)

ECOG, eastern cooperative oncology group; mPDAC, metastatic pancreatic ductal
adenocarcinoma; PDAC, pancreatic ductal adenocarcinoma, SD, standard deviation.
a
Patients may have ≥1 value reported. Therefore, the sum of the percentages may be
greater than 100%.
b
Other metastatic sites included abdominal wall, adrenal glands, ascites, chest wall,
diaphragm, gastric, gluteus muscle, kidney, ovary, pelvis, right adnexa, serosa, spleen,
and thyroid.
c
The listed comorbid conditions belong to the Charlson Comorbidity Index.

Real-World Effectiveness

information, approximately 74% of patients had a baseline
ECOG performance status of 0-1. Diabetes without end-organ
damage was the most common comorbid condition, present in
25.4% of patients.
Table 2 provides information on 312 patients who received
treatment in the metastatic setting prior to liposomal irinotecan.
Gemcitabine-based therapy was received among 93.9% of
patients. Table 3 details liposomal irinotecan treatment

Overall, 263 (70.3%) patients died, and 328 (87.7%) patients
experienced disease progression or died over the observation
period. The overall median (95% CI) OS from mPDAC diagnosis
was 18.4 [16.1, 19.9] months and 9.6 (6.7, 14.3), 15.6 (13.5, 20.4), and
20.9 [19.1, 23.4] for patients treated with liposomal irinotecan in 1L,
2L, and 3L+, respectively (Figure 2). The overall median [95% CI]

TABLE 3 | Liposomal irinotecan treatment characteristics in the
metastatic setting.
TABLE 2 | Treatment patterns in the metastatic setting prior to liposomal
irinotecan-based treatment.

N = 374
Duration of liposomal irinotecan (months), median [95% CI]
All patients
1L (n=62)
2L (n=156)
3L+ (n=156)
Prior irinotecan in the metastatic setting, n (%)
All patients
2L (n=156)
3L+ (n=156)
Liposomal irinotecan dosage, n (%)
Patients with dose information available
Patients with dose modiﬁcations, n (%)
Patients with dose reduction, n (%)
Treatments concomitant with liposomal irinotecan, n (%)a
5-FU/(LV)
Other
GCSF
Pegﬁlgrastim
Filgrastim
Tbo-ﬁlgrastim
Filgrastim-sndz
GCSF with ﬁrst administration of liposomal irinotecanb
Any 5-FU (alone or in combination)

N = 374
Duration of metastatic treatments prior to liposomal
irinotecan (months), mean ± SD [median]a
Treatment regimens prior to liposomal irinotecan, n (%)b,c
Gemcitabine (alone or in combination)
Gem + nab-P
Gemcitabine
Gem + nab-P + cisplatin
Gem + cisplatin
Gem + paclitaxel
5-FU (alone or in combination)
FOLFIRINOX
FOLFOX
FOLFIRI
5-FU/(LV)
Any irinotecan (alone or in combination), n (%)
Received irinotecan (alone or in combination) in the line
of therapy prior to the ﬁrst administration of liposomal
irinotecan, n (%)

9.4 ± 8.4 [7.0]
312
293 (93.9)
226 (77.1)
48 (16.4)
9 (3.1)
7 (2.4)
5 (1.7)
122 (39.1)
83 (68.0)
37 (30.3)
32 (26.2)
15 (12.3)
92 (29.5)
12 (3.8)

5-FU, 5-ﬂuorouracil; FOLFIRI, 5-FU + leucovorin + irinotecan; FOLFIRINOX, 5-FU +
leucovorin + irinotecan + oxaliplatin; FOLFOX, 5-FU + leucovorin + oxaliplatin; Gem,
gemcitabine; LV, leucovorin or levoleucovorin; mPDAC, metastatic pancreatic ductal
adenocarcinoma; nab-P, nab-paclitaxel; PEGPH20, PEGylated recombinant human
hyaluronidase; SD, standard deviation.
a
Treatment duration was deﬁned as cumulative duration of any treatment regimen. It was
calculated among patients who had any treatment prior to liposomal irinotecan initiation.
b
Patients may have ≥ 1 value reported. Therefore, the sum of the percentages may be
greater than 100%.
c
Treatment regimens were categorized by grouping together treatments that were initiated
within 30 days of each other.
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1.6
2.8
2.1
1.4

[1.4,
[1.4,
[1.6,
[1.3,

1.9]
5.6]
2.8]
1.6]

92 (29.5)
2 (1.3)
90 (57.7)
367
116 (31.6)
108 (29.4)
358 (95.7)
4 (1.1)
80 (21.4)
75 (93.8)
14 (17.5)
3 (3.8)
1 (1.3)
26 (7.0)
374 (100.0)

5-FU, 5-ﬂuorouracil; CI, conﬁdence interval; GCSF, granulocyte colony stimulating factor;
LV, leucovorin; m, meter; mg, milligram; mPDAC, metastatic pancreatic ductal
adenocarcinoma; SD, standard deviation.
a
Patients may have ≥ 1 value reported. Therefore, the sum of the percentages may be
greater than 100%.
b
Patients that had GCSF administered between one and four days after index date are
displayed, based on the NCCN Guidelines on Hematopoietic Growth Factors, Version
2.2020.
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FIGURE 2 | Kaplan-Meier Analysis of Overall Survival from mPDAC Diagnosis among Patients with mPDAC Treated with Liposomal Irinotecan in a Doublet
with 5-Fluorouracil.

with liposomal irinotecan in 3L+ vs. 2L had a signiﬁcantly higher risk
of death [HR: 1.90 (1.38, 2.63), p: < 0.001]. Patients with liver
metastases [1.59 (1.19, 2.11), p: 0.002], brain metastases [6.53 (1.83,
23.29), p: 0.004], and congestive heart failure (3.01 [1.45, 6.26], p:
0.003) also had a signiﬁcantly higher risk of death.
In the model examining PFS, patients treated with liposomal
irinotecan in 3L+ vs. 2L also had a signiﬁcantly higher risk of tumor
progression/death [HR (95% CI): 1.99 (1.49, 2.65), p: < 0.001].
Consistent with OS, patients with liver metastases [1.63 (1.26, 2.10),

OS from the index date was 6.1 (5.1, 6.8) months and 8.0 (5.1, 11.2),
7.3 (5.3, 8.8), and 4.6 (4.0, 5.7) months for patients treated with
liposomal irinotecan in 1L, 2L, and 3L+, respectively (Figure 3). The
overall median [95% CI] PFS was 2.5 (2.2, 2.8) months and 4.2 (2.2,
6.6), 3.0 (2.6, 3.7), and 2.0 (1.7, 2.2) for patients treated with
liposomal irinotecan in 1L, 2L, and 3L+, respectively (Figure 4).
The results of the multivariate Cox model analyzing the association
between the baseline characteristics and effectiveness outcomes are
presented in Table 4. In the model examining OS, patients treated

FIGURE 3 | Kaplan-Meier Analysis of Overall Survival from Initiation of Treatment with Liposomal Irinotecan among Patients with mPDAC Treated with Liposomal
Irinotecan in a Doublet with 5-Fluorouracil.
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FIGURE 4 | Kaplan-Meier Analysis of Progression Free Survival among Patients with mPDAC Treated with Liposomal Irinotecan in a Doublet with 5-Fluorouracil.

Similarly, Glassman et al. reported an overall median OS of 5.3
months and longer OS in patients receiving liposomal irinotecan
in earlier lines of therapy (7). Thus, the observed survival trends
among patients treated with liposomal irinotecan in 1L, 2L and
3L+ are similar to other real world studies. In addition, this study
found in adjusted analyses that patients treated with liposomal
irinotecan in 3L+ vs. 2L had signiﬁcantly higher risk of death.
This study also reported that patients treated with liposomal
irinotecan in earlier vs. later lines of therapy had better PFS.
These results demonstrate the clinical beneﬁt of being treated
with liposomal irinotecan in earlier vs. later lines of therapy,
which may be attributed to common resistance mechanisms,
more severe disease, and worse prognosis/performance status in
patients with each subsequent line of therapy.
To complement the OS and PFS beneﬁt conferred by liposomal
irinotecan, this study also described the safety proﬁle of liposomal
irinotecan in patients that were older and had poorer baseline
performance status when compared to the pivotal NAPOLI-1 trial.
It is noted that due to the real-world nature of this study, AEs may
not have been recorded as often as AEs in clinical trials where
patients are monitored more closely. Compared to other realworld settings, this study had a lower proportion of patients with
grade 3 or 4 neutropenia than that previously reported in the
community setting (8% vs. 11%) (9), and a slightly higher
proportion of patients with various grade 3 or 4 AEs than in
Glassman et al. (7). Overall, this study further supports the known
safety proﬁle and use of liposomal irinotecan.
Findings from this study may inform treatment
recommendations for patients with mPDAC. Currently, the
NCCN recommends liposomal irinotecan as a 2L therapy for
patients with mPDAC and good performance status following
treatment with a gemcitabine-based regimen (10). They do not
list any recommended treatments for 1L or 3L+ for patients with
mPDAC. This real-world study indicates promising survival
among patients treated with liposomal irinotecan in 3L+, and

p: < 0.001] and congestive heart failure [2.53 (1.29, 4.99), p: 0.007]
had signiﬁcantly higher risk of tumor progression/death.

Grade 3 or 4 Adverse Events
The most common grade 3 or 4 symptom-related AEs were fatigue/
asthenia (4.0%), diarrhea (3.2%), and vomiting (1.6%). The most
common grade 3 or 4 laboratory abnormalities were anemia
(21.1%), lymphopenia (12.6%), and neutropenia (7.8%) (Table 5).

DISCUSSION
From six academic centers, 374 patients with mPDAC treated
with liposomal irinotecan in a doublet with 5-FU were examined.
The results of this retrospective, observational chart review study
indicate that patients with mPDAC treated with liposomal
irinotecan in the real-world setting compared to the pivotal
phase 3 clinical trial (NAPOLI-1) (3) were older (median age:
69 vs. 63 years), had poorer ECOG performance status (ECOG <2:
74% vs. 91%), and had received more lines of therapy prior to
liposomal irinotecan (2+ prior lines of therapy: 42% vs. 34%).
Nonetheless, the median OS in this study was identical to data
reported in the NAPOLI-1 trial (median OS: 6.1 months) (3). This
study’s results are also consistent with those from a real-world
Flatiron study on patients with mPDAC treated with liposomal
irinotecan in the community setting and reinforce the conclusions
from the Glassman et al. study (7, 9).
Overall, liposomal irinotecan was effective for treatment of
mPDAC in the study population, particularly among those
receiving it in earlier lines of therapy. Patients treated with
liposomal irinotecan in 1L, 2L, and 3L+ had median OS of 8.0
months, 7.3 months, and 4.6 months, respectively. This trend
was similarly reported in the Flatiron study where patients
treated with liposomal irinotecan in 1L, 2L, and 3L+ had
median OS of 6.9, 5.4, and 4.0 months, respectively (9).
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6

July 2021 | Volume 11 | Article 678070

Yu et al.

Liposomal Irinotecan for mPDAC

TABLE 4 | Associations between Baseline Characteristics and Effectiveness Outcomes of Liposomal Irinotecan - Multivariate Analysis.
OS
N = 374

Age at index date
Male (ref: female)
Race/Ethnicity (ref: white)
Black/African-American
Hispanic/Latino
Asian/Paciﬁc Islander and Native American/American Indian
Unknown
Geographic Location
(ref: northeast)
Midwest
South
West
Time from mPDAC diagnosis to index (months)
Cancer stage at ﬁrst diagnosis of PDAC (ref: metastatic)
Non-metastatic
Unknown
Line of therapy for liposomal irinotecan (ref: 2L)
1L
3L+
Primary tumor location in pancreas (ref: head)
Body
Body and tail
Neck or neck and body
Tail
Unknown
Metastatic sites
Liver
Brain
Number of metastatic sites
(ref: 1)
2
3 or more
ECOG (ref: < 2)
≥2
Unknown
Selected comorbidities
Congestive heart failure

PFS
N = 374

HR

95% CI

P-value3

HR

95% CI

P-value3

1.00
1.18

(0.98, 1.01)
(0.92, 1.53)

0.792
0.189

0.99
1.05

(0.98, 1.01)
(0.84, 1.32)

0.248
0.669

1.14
0.88
0.80
0.79

(0.72,
(0.43,
(0.47,
(0.45,

1.82)
1.81)
1.37)
1.40)

0.569
0.736
0.413
0.424

0.92
1.03
0.79
0.63

(0.62,
(0.52,
(0.50,
(0.37,

1.36)
2.05)
1.25)
1.07)

0.673
0.940
0.316
0.088

0.79
0.60
0.46
0.98

(0.47,
(0.38,
(0.29,
(0.96,

1.35)
0.94)
0.73)
1.00)

0.394
0.026*
<0.001*
0.013*

1.00
0.98
0.65
0.97

(0.62,
(0.68,
(0.44,
(0.96,

1.61)
1.42)
0.96)
0.99)

0.999
0.923
0.030*
0.001*

0.84
0.77

(0.60, 1.18)
(0.41, 1.43)

0.313
0.406

0.91
0.80

(0.67, 1.23)
(0.49, 1.31)

0.525
0.372

0.80
1.90

(0.51, 1.27)
(1.38, 2.63)

0.349
<0.001*

0.78
1.99

(0.52, 1.18)
(1.49, 2.65)

0.246
<0.001*

0.70
0.83
0.81
1.01
0.46

(0.49,
(0.53,
(0.10,
(0.70,
(0.06,

1.00)
1.33)
6.23)
1.45)
3.41)

0.048*
0.443
0.838
0.970
0.448

0.62
0.72
0.27
1.22
0.65

(0.45,
(0.47,
(0.04,
(0.89,
(0.20,

0.004*
0.125
0.199
0.222
0.479

1.59
6.53

(1.19, 2.11)
(1.83, 23.29)

0.002*
0.004*

1.63
2.53

(1.26, 2.10)
(0.73, 8.74)

<0.001*
0.144

0.99
1.09

(0.67, 1.45)
(0.65, 1.81)

0.941
0.744

1.18
1.05

(0.85, 1.64)
(0.68, 1.62)

0.316
0.842

1.21
1.09

(0.87, 1.69)
(0.72, 1.65)

0.254
0.699

1.01
1.12

(0.75, 1.34)
(0.77, 1.62)

0.970
0.555

3.01

(1.45, 6.26)

0.003*

2.53

(1.29, 4.99)

0.007*

0.86)
1.10)
2.00)
1.68)
2.15)

CI, conﬁdence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; mPDAC, metastatic pancreatic ductal adenocarcinoma; OS, overall survival; PDAC, pancreatic
ductal adenocarcinoma; PFS, progression free survival.
*indicates p-value <0.05.

patients in this study despite not being indicated for front-line
use; this could be due to several reasons: failure of adjuvant
gemcitabine-based therapy, possible neuropathy, or patient/
provider preferences based on toxicity proﬁles. This study
therefore describes real-world use of liposomal irinotecan in
circumstances where patients may not exactly ﬁt clinical trial
entry criteria.
There are several limitations to consider when interpreting
ﬁndings from this study. Due to the non-randomized,
retrospective nature of the study, residual confounding may
impact the associations and conclusions identiﬁed. Speciﬁcally,
residual confounding may have remained for the comparative
analyses by line of therapy even after adjustment (e.g., patients
receiving liposomal irinotecan in 3L may have been sicker than
those receiving liposomal irinotecan in 1L). The results reported
are based on data collected at academic cancer centers and may
not be generalizable to patients with mPDAC treated in other

TABLE 5 | Grade 3 or 4 symptom-related adverse events and
laboratory abnormalities.
N = 374
Symptom-related adverse events, n (%)
Fatigue/asthenia
Diarrhea
Vomiting
Nausea
Laboratory abnormalities, n (%)
Anemia
Lymphopenia
Neutropenia

15 (4.0)
12 (3.2)
7 (1.9)
6 (1.6)
79 (21.1)
47 (12.6)
29 (7.8)

may support using liposomal irinotecan in later lines of therapy
when other treatment options are not available. Additionally,
liposomal irinotecan was used as 1L therapy in a number of
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settings. Real-world evidence from medical charts is also limited
by the availability of clinical data reported in the medical chart,
although quality assurance procedures and data checks served to
maximize data integrity. In addition, in analyses where less
common conditions such as brain metastases or certain
comorbidities are examined, the smaller number of patients
with these conditions could limit the ability for robust
conclusions. However, the ﬁndings from this study are
corroborated by existing literature that report poorer
prognostic outcomes among patients with pancreatic cancer
who have brain metastases or comorbidities (11, 12).
Furthermore, this study overall included a large number of
patients to describe the current treatment landscape for
mPDAC and evaluate NAPOLI-1-based liposomal irinotecan
doublet regimens in the real-world setting. Baseline
information on AEs were not collected, so it is unclear if the
AE data reported are treatment emergent (i.e., associated with
liposomal irinotecan). The assessments of disease progression
and AE grading in real-world settings may be based on
heterogeneous criteria and assessment schedules across subjects
and centers. For example, PFS may be overestimated if the
patient’s visit and evaluation of progression was recorded in
the patient’s chart later than the actual date of progression itself.
Poor prognosis among patients with mPDAC necessitates
continuous research on efﬁcacious and better tolerated
treatments to improve patient outcomes. This real-world study
found that patients treated with liposomal irinotecan were older,
sicker, and had more lines of therapy prior to liposomal irinotecan
than those in the NAPOLI-1 registrational trial; however, realworld effectiveness was similar. Furthermore, patients were treated
with liposomal irinotecan in 3L+, a setting with no currently
approved options, and demonstrated clinical beneﬁt.
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